Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Elizabeth do Espirito Santo Cestario, Jose Fernando Vilela-Martin, Luciana Neves Cosenso-Martin, Tatiane Azevedo Rubio, Jessica Rodrigues Roma Uyemura, Valquiria da Silva Lopes, Letícia Aparecida Barufi Fernandes, Lucia Helena Bonalume Tacito, Heitor Moreno Junior & Juan Carlos Yugar-Toledo. (2022) Effect of Sequential Nephron Blockade versus Dual Renin-Angiotensin System Blockade Plus Bisoprolol in the Treatment of Resistant Hypertension, a Randomized Controlled Trial (Resistant Hypertension on Treatment - ResHypOT). Vascular Health and Risk Management 18, pages 867-878.
Read now
Read now
Articles from other publishers (13)
I. G. Yudin & V. V. Fomin. (2023) Uncontrolled and resistant arterial hypertension: prevalence, methods of modification of therapy. Systemic Hypertension 19:4, pages 31-35.
Crossref
Crossref
A. V. Aksenova, E. V. Oshchepkova, A. A. Orlovsky & I. E. Chazova. (2022) Analysis of lifestyle modifications and antihypertensive therapy in patients with arterial hypertension and chronic kidney disease (data from the national registry). Systemic Hypertension 19:2, pages 39-46.
Crossref
Crossref
Maja Milošević & Petar Otašević. (2022) Treatment-resistant hypertension. Arhiv za farmaciju 72:1, pages 1-19.
Crossref
Crossref
Maja Milošević & Petar Otašević. (2022) Spironolacton in the therapy of resistant hypertension. Galenika Medical Journal 1:1, pages 29-37.
Crossref
Crossref
Sofia Pereira, Liliana Carvalho, Madalena Costa, Armindo Melo, Isabel Ferreira, Celso Gomez-Sanchez, Mariana Monteiro, Gavin Vinson & Duarte Pignatelli. (2021) Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology. Biomedicines 9:4, pages 441.
Crossref
Crossref
M. S. Litvinova, L. A. Khaisheva & S. V. Shlyk. (2020) Resistant hypertension: focus on vascular lesions. South Russian Journal of Therapeutic Practice 1:3, pages 16-26.
Crossref
Crossref
Lida Feyz, Sjoerd van den Berg, Robert Zietse, Isabella Kardys, Jorie Versmissen & Joost Daemen. (2020) Effect of renal denervation on catecholamines and the renin–angiotensin–aldosterone system. Journal of the Renin-Angiotensin-Aldosterone System 21:3, pages 147032032094309.
Crossref
Crossref
V. O. Shidlovskyі, O. V. Shidlovsky, O. A. Tovkai, I. M. Pavlovskyi & V. V. Kravtsiv. (2020) МЕДИКАМЕНТОЗНЕ ЛІКУВАННЯ ПЕРВИННОГО ГІПЕРАЛЬДОСТЕРОНІЗМУ. Здобутки клінічної і експериментальної медицини:4, pages 6-14.
Crossref
Crossref
M. Elizabeth Moss, Brigett Carvajal & Iris Z. Jaffe. (2019) The endothelial mineralocorticoid receptor: Contributions to sex differences in cardiovascular disease. Pharmacology & Therapeutics 203, pages 107387.
Crossref
Crossref
Omar Azzam, Marcio G. Kiuchi, Jan K. Ho, Vance B. Matthews, Leslie Marisol Lugo Gavidia, Janis M. Nolde, Revathy Carnagarin & Markus P. Schlaich. (2019) New Molecules for Treating Resistant Hypertension: a Clinical Perspective. Current Hypertension Reports 21:10.
Crossref
Crossref
Elizabeth Silaid Muxfeldt, Bernardo Chedier & Cibele Isaac Saad Rodrigues. (2019) Resistant and refractory hypertension: two sides of the same disease?. Brazilian Journal of Nephrology 41:2, pages 266-274.
Crossref
Crossref
Antonis A. Manolis, Theodora A. Manolis, Helen Melita & Antonis S. Manolis. (2019) Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men’s Issue?. Current Hypertension Reports 21:3.
Crossref
Crossref
O. B. Kuzmin, V. V. Zhezha, L. N. Landar & O. A. Salova. (2019) RESISTANT ARTERIAL HYPERTENSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: PREVALENCE, PROGNOSTIC SIGNIFICANCE, REASONS AND APPROACHES TO ANTIHYPERTENSIVE THERAPY. Nephrology (Saint-Petersburg) 23:1, pages 37-44.
Crossref
Crossref